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No patient had any symptom of heart disease. Only borderline abnormalities of ECG or echocardiogram were observed in 12 patients. One of them showed a moderate aortic stenosis which was known before the treatment; apical or septum hypokinesia were present in four patients and one patient had a slightly right ventricular dilatation.
Twelve (16%) chest radiographs showed moderate or severe abnormalities, but there was no significant correlation between the results of pulmonary function tests and Xenon ventilation/perfusion scintigraphy, the clinical examination and the intensity of the radiological sequelae. Twenty-nine (64%) Xenon scintigraphies showed a reduction of lung perfusion in the irradiated areas without any symptom. The resting mean pulmonary function test was significantly lower for the patients than for the control group with regard to Total Capacity and Vital Capacity. The exercise tolerance, as indicated by analysis of blood gases, was below the one expected for only two patients who were dyspneic during the low level of exercise. We did not find any significant difference between the three treatment groups.
We conclude that the treatment with mantle field under good technical conditions (high energy photons, moderate doses ...) can result in minimal cardiopulmonary dysfunction.
Hodgkin's disease (HD) is a prototype for the successful management of a previously incurable malignancy by the use of an aggressive multimodal therapy. This results from extended field megavoltage irradiation and/or combination of chemotherapeutic agents which can be administered alternately with radiation or sequencially. Since about 85-90% of the patients in early stages of Hodgkin's disease can now be cured (Kaplan, 1980; Tubiana et al., 1985) , the problem of late toxicity of the various treatment methods is now prevailing. At least for limited stages, the role of the radiotherapist is currently not only to cure the disease, but also to minimise the risk of late complication.
Mantle field irradiation for the treatment of Hodgkin's disease subject the heart and lungs to varying radiation doses depending on the presence and extent of the intrathoracic disease and on the radiation techniques used.
The literature contains a number of reports on both cardiac and pulmonary complications, often severe, following mantle field irradiation, but many of these reports concern treatment techniques now considered as out of date (Applefeld et al., 1982; Do Pico et al., 1979; Gottdiener et al., 1983; Host & Yale, 1973; Larson et al., 1976; Lokich et al., 1973) . More recent data suggest a dramatic decrease in these sequelae over the past decade as a result of refined treatment techniques (Carmel & Kaplan, 1976; Morgan et al., 1985; Smith et al., 1989) . However, sequelae are still too frequent in the recent literature (Cosset et al., 1984; Cossett et al., 1988; LaMonte et al., 1986; Pohjola-Sintonen et al., 1987; Zarrabi et al., 1984; Zucali et al., 1981 Irradiation was applied to all patients in the same institution from a 25 MV photon beam from a linear accelerator (Sagittaire CGR) with two opposed mantle fields as defined by KAPLAN (Kaplan, 1980 Forty-five Xenon 133 ventilation/perfusion scintigraphies were performed with the technique described by LACOSTE (Lacoste et al., 1980 (MET) . MET was determined with the maximal theoretical heart rate given by the following formula: 220 -age of the patient (Astrand, 1952; Astrad & Rodahl, 1970) . The constant maximal power test was determined after the maximal supported power (MSP) was measured for 20 mn (Gimenez et al., 1984) .
Arterial blood gases were obtained before and at the end of the exercise. The heart rate (HR) was checked continuously. The blood pressure (BP) was determined by auscultation. HR and BP were obtained at rest, during every further minute of exercise, immediately following the peak exercise and during each minute of recovery until HR decreases to 100 beats per minute.
The analysis of blood gases was performed to determine the modifications of P02, PCO2, pH and SaO2. The modifications of blood gases during maximal exercise is widely accepted as one of the most objective measurement of the physical fitness of individuals as reflected by their respiratory and cardiovascular system. The major determinant of pH and SaO2 during the maximal theoretical exercise MET are the cardiac output and the oxidative capacity of the skeletal muscle. Therefore, a fall in the pH and SaO2 during MET is found in patients with decreasing cardiopulmonary function (Gimenez et al., 1984) .
Echocardiography An echocardiography was performed in 73 patients with 2-d and M-mode echocardiographic recording. The ejection fraction was calculated according to the Teicholtz's formula (Teicholtz et al., 1976) .
For the analysis, we used a specific statistical data base management system developed at the Institut Gustave Roussy (Villejuif, France) (Wartelle et al., 1983) . The Student's test and Chi square test were used to compare the various treatment groups for all parameters. A P value <0.05 was accepted as statistically significant.
Results

Symptomatology
No patient presented with cardiac symptoms; only three patients felt that they were more dyspneic during exercise than before treatment, due to two of them to post surgical phrenic paralysis and for the third one to an isolated restrictive syndrome.
Chest radiographs
The results of chest radiographs are summarised in Table II. There was no significant correlation between the results of pulmonary function test, clinical examination and the intensity of the radiological sequelae. In two patients, the radio- The mean values of the treatment groups were within the normal limits (20% of predicted normal value) for all parameters except for Vital Capacity (VC) and Total Capacity (TC). The treatment groups, which included mantle irradiation, showed mean VC and TC that were lower than the control values (Table III) Only one patient, who was dyspneic during exercise, had a significant decrease in SaO2 but not of pH. The other patient, who was very dyspneic because of phrenic paralysis, refused the exercise test. One patient with phrenic paralysis, but who had a sport activity, had normal of pH and SaO2 values during effort.
Discussion
The incidence of electrocardiographic abnormalities in patients who recieve mantle irradiation is low compared to other reports. Generally, a 25% incidence of findings including ST segment depression, T wave changes, minor QRS abnormalities and occasional silent myocardial infarction are reported (Brosius et al., 1981; LaMonte et al., 1986; Larson et al., 1976; McReynolds et al., 1976; Pohjola-Sintonen et al., 1987; Watchie et al., 1987; Zarrabi et al., 1984) . Watchie et al. (1987) found a 13% incidence of complete or incomplete right bundle branch blocks. We report only seven (9%) abnormal ECG. Six had minor abnormalities.
The incidence (5%) of pericardial effusion is low in this series. Pohjola et al. (1987) reported an incidence of 38% of pericardial effusion more than 5 years after mediastinal irradiation. Gottdiener et al. (1983) gave 36%. However a pericar- (1976) .
Two patients of our series had a history of pericarditis 6 months after treatment. One of them presented with pericardial effusion which completely regressed in 3 months with medical treatment; the second one presented with a huge pericardial effusion treated by surgical drainage; both were asymptomatic respectively 36 and 45 months later. At the time of the echocardiography, it was not possible to report any pericardial effusion.
Nevertheless, we are describing only clinical pericardial effusions since we did not check them carefully during treatment in all patients by echocardiography. Had we used this procedure, the incidence of abnormalities would probably be higher. In our study, the echocardiography was performed, at the time of the study, 3 years or more after the end of treatment. Morgan et al. (1985) who performed echocardiography more than 5 years after the end of treatment found 8% of minor pericardial effusion. However, we attribute this lower incidence to the use of equally weighed fields treated every day by high energy Linac and to the use of a limited dose of 36 Gy in the mediastinum in patients in complete remission with no enlarged mediastinal nodes. Burns et al. (1983) found a 57% incidence of abnormal ventricular function, but those patients had recieved doses of irradiation of up to 76 Gy which excess the therapeutic range. A similar incidence of abnormalities of ventricular function was reported by Gottdiener et al. (1983) . Nevertheless, this group had been treated with a single anteroposterior field, a technique that is not commonly used. Both last studies included older patients who have an increased likelihood of concomitant coronary artery disease and neither study evaluated other possible causes of ventricular dysfunction. Morgan et al. (1985) for patients under 35 years found 25% of ventricular abnormalities with sensitive radionuclide ventriculography.
We found abnormal ventricular function only in 6%. This incidence of cardiac abnormality is less than previously reported and partially reflects the selection of patients for study, but probably the low sensitivity of the echocardiography too. However, we can be sure that our patients do not present with serious cardiac sequelae.
The linear accelerator of 25 MV used, gives a lower dose to the heart than 'Co or 8 MV LinAc as described in other studies (Brosius et al., 1981; Carmel & Kaplan, 1976; Cosset et al., 1984; La Monte et al., 1986; Larson et al., 1976; McReynolds et al., 1976; Pohjola-Sintonen et al., 1987; Watchie et al., 1987; Zarrabi et al., 1984) ; 1.8 Gy to a maximum of 2 Gy per fraction, five fractions per week, the two fields being treated every day, all these precautions are probably important to reduce late sequelae. Nevertheless, our follow-up is still too short to conclude. The cardiovascular sequelae were too low to be compared between the different treatment groups. Santoro et al. (1982; and Cosset et al. (1989) showed that pulmonary toxicity was more important with ABVD. However, in our series, it was not possible to confirm these results as the follow-up was still too short.
Previous studies evaluating the effects of mantle irradiation on pulmonary function found a significant decrease in Total Lung Capacity, Vital Capacity, Inspiratory Capacity, and Diffusion Capacity associated with radiological infiltrative signs, 2 to 6 months after completion of the treatment. They disagree as to whether these modifications lessen over 1 to 2 years following the treatment (Lokich et al., 1973) .
Several researchers have examined the short-term effects of mantle irradition on lung function. Findings include acute but transient decreases in PFTs over the first 6 months with return to pretreatment values by 8-12 months (DoPico et al., 1979; Evans et al., 1974; Smith et al., 1989) . Nevertheless Zuccali et al. (1981 ), or Pohjola (1987 reported a significant decrease in vital capacity and inspiratory capacity in 30% of the patients, sometimes severe, more than 12 months after treatment. The follow-up of the patients in our series lasted more than 2 years and can explain our low sequelae level. Host et al. (1973) and Larson et al. (1976) evaluated the effects of mantle irradiation and found a mild restrictive ventilatory impairment marked by a decrease in lung volume at 9-23 months. Smith et al. (1989) confirmed acute changes in lung volumes and spirometry after mantle irradiation, which resolve within 2 years and are not of sufficient degree to cause symptomatology or to extend outside the range of normal.
There is much less information available on the late effects of mantle irradiation on pulmonary function. Morgan et al. (1985) and Smith et al. (1989) found only minor reduction in lung volume and moderate decrease in DL CO at more than 4 years of follow-up. Watchie et al. (1987) or Tarbell et al. (1990) showed that the use of either chemotherapy followed by radiotherapy might minimise functional changes. In our study, the size of the mediastinal volume, evaluated by the position of the cardiac surface irradiated allows to state that over 75% the tolerance to exercise measured by the diminution of the blood pH and of the SaO2 is less good; and there is a tendency to a diminution of the pulmonary volume. It seems that the importance of the mediastinal volume irradiated affects the cardiorespiratory function after the treatment. It is probably difficult to evidence it in this method since the variations are light as the incidence of the sequelae. The comparison with the Watchie's study that involved extensive radiotherapy is difficult.
We did not find a significant decrease in exercise performance. Two patients were dyspneic during low level of exercise, but one had phrenic paralysis. The second patient who also had a phrenic paralysis, had an excellent reeducation and his functional exercise test was in the normal limits.
Our study indicates that mantle field radiotherapy for Hodgkin's disease produces few functionally significant sequelae at long term follow-up despite the reduction of the lung perfusion in the irradiated areas showed by Xenon scintigraphy. It seems, with our study, that any technique improvements such as attention to the fractionation schedule, in vivo dosimetry, high energy Linac, reduction of the mediatinal volume irradiated by chemotherapy etc...., may reduce the incidence of cardiopulmonary abnormalities. Therefore, the therapeutic trials for Hodgkin's disease must not only address the question of survival and cure but the reduction of late effects in those 80-90% of the patients that will be long term survivors.
